Co-Authors
This is a "connection" page, showing publications co-authored by JEFFREY N MYERS and ABDULLAH A OSMAN.
Connection Strength
3.828
-
Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2023 04 03; 29(7):1344-1359.
Score: 0.930
-
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Res. 2015 Apr 01; 75(7):1205-15.
Score: 0.530
-
Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Mol Cancer Ther. 2015 Feb; 14(2):608-19.
Score: 0.523
-
Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Adv Radiat Oncol. 2022 Nov-Dec; 7(6):100989.
Score: 0.219
-
Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress. Mol Cancer Ther. 2021 07; 20(7):1257-1269.
Score: 0.204
-
Loss of p53 drives neuron reprogramming in head and neck cancer. Nature. 2020 02; 578(7795):449-454.
Score: 0.187
-
COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. Clin Cancer Res. 2019 09 15; 25(18):5650-5662.
Score: 0.180
-
Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity. Oral Oncol. 2018 12; 87:49-57.
Score: 0.171
-
Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation. Clin Cancer Res. 2017 Nov 01; 23(21):6541-6554.
Score: 0.157
-
Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins. Clin Cancer Res. 2015 Nov 01; 21(21):4831-44.
Score: 0.136
-
Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol Cell. 2014 Jun 19; 54(6):960-974.
Score: 0.126
-
FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner. Clin Cancer Res. 2024 01 05; 30(1):187-197.
Score: 0.061
-
TP53 gain-of-function mutation modulates the immunosuppressive microenvironment in non-HPV-associated oral squamous cell carcinoma. J Immunother Cancer. 2023 08; 11(8).
Score: 0.059
-
Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. Br J Cancer. 2023 06; 128(11):2013-2024.
Score: 0.058
-
Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma. Commun Biol. 2022 07 28; 5(1):757.
Score: 0.055
-
Local Anti-PD-1 Delivery Prevents Progression of Premalignant Lesions in a 4NQO-Oral Carcinogenesis Mouse Model. Cancer Prev Res (Phila). 2021 08; 14(8):767-778.
Score: 0.051
-
Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer. J Natl Cancer Inst. 2020 03 01; 112(3):266-277.
Score: 0.047
-
Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1. Oncogene. 2018 03; 37(10):1279-1292.
Score: 0.040
-
Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Res. 2015 Apr 01; 75(7):1527-36.
Score: 0.033
-
The p53-reactivating small molecule RITA induces senescence in head and neck cancer cells. PLoS One. 2014; 9(8):e104821.
Score: 0.032
-
Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther. 2013 Sep; 12(9):1860-73.
Score: 0.030